文献速递烧伤

帕米膦酸治疗烧伤患者高钙血症的剂量反应

Pamidronate Dose Response for Hypercalcemia in Burn-Injured Patients.
PubMed 文献 · J Burn Care Res · 2026-01-01

主要剂量为30mg(96.2%),第7天和第14天离子钙绝对下降均为-0.26 mmol/L,低钙血症发生率为13.5%。提示帕米膦酸可有效降低烧伤后高钙血症的离子钙水平。

要点

  • 烧伤后高钙血症可用静脉帕米膦酸治疗,常用剂量30mg。
  • 治疗后第7天和第14天离子钙平均下降约0.26 mmol/L。
  • 低钙血症发生率为13.5%,需监测血钙并备钙剂。

核心结论

  • 静脉帕米膦酸用于烧伤后高钙血症可有效降低离子钙水平。

主要发现

  • 平均年龄44.4±16.0岁,85%为男性,平均烧伤总面积60.2±22.2%。
  • 96.2%的静脉帕米膦酸剂量为30mg,平均峰值离子钙1.45±0.11 mmol/L。
  • 第7天离子钙绝对下降-0.26±0.12 mmol/L(-17.1±7.3%),第14天下降-0.26±0.13 mmol/L(-17.0±7.5%)。
  • 5次给药后发生低钙血症(13.5%),需钙替代治疗。

临床怎么用

  • 对烧伤后高钙血症成人患者可考虑静脉帕米膦酸30mg,并监测离子钙及低钙血症。

局限性

  • 回顾性观察设计、样本量小,证据级别有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hypercalcemia after a burn injury is attributed to bone resorption secondary to muscle inactivity and prolonged immobilization. Evidence to guide treatment is extremely limited. The purpose of this study was to assess the effect of pamidronate on hypercalcemia in patients with burn injuries. This retrospective, observational study was conducted at a regional burn center. Adult patients admitted to the burn surgery service who received IV pamidronate for hypercalcemia during hospitalization were included. The primary outcome was the change in ionized calcium (iCa) at days 7 and 14 after pamidronate treatment. Secondary outcomes included hypocalcemia and the requirement for calcium replacement. Descriptive statistics were used to evaluate the outcomes. Mixed-effects regression analyses were performed to estimate the direction and magnitude of the effects of clinical factors on changes in iCa. Twenty-seven patients and 37 courses of therapy were included for analysis. The mean age was 44.4 ± 16.0 years, 85% were male, and the mean total body surface area (TBSA) burned was 60.2 ± 22.2%. The majority of IV pamidronate doses were 30 mg (96.2%). The mean peak iCa was 1.45 ± 0.11 mmol/L. The absolute decrease in iCa was -0.26 ± 0.12 mmol/L (-17.1 ± 7.3%) and -0.26 ± 0.13 mmol/L (-17.0 ± 7.5%) at day 7 and day 14, respectively. Hypocalcemia occurred after 5 pamidronate administrations (13.5%). The use of IV pamidronate for the management of hypercalcemia postburn injury appeared effective in decreasing iCa levels. Future studies are needed to further evaluate the clinical implications of these findings.

来源:J Burn Care Res,查看原文。版权归原作者所有。

引用

  1. Imani G, Louie E, Young S, et al. Pamidronate Dose Response for Hypercalcemia in Burn-Injured Patients. J Burn Care Res. 2026. PMID: 42207149. doi:10.1093/jbcr/irag081

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。